Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nausea and Vomiting Clear all
Completed Phase 3 Interventional
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced May 21, 2026, 4:39 PM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
3mg AZ-010, 1mg AZ010, Staccato Placebo
Combination Product
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Lancaster, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
PONV
Interventions
Palonosetron only, Palonosetron with Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced May 21, 2026, 4:39 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Postoperative Pain, Postoperative Nausea and Vomiting, Quality of Life, Breast Cancer, Breast Prosthesis; Pain
Interventions
Pre-pectoral Tissue Expander
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced May 21, 2026, 4:39 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HIV Infections
Interventions
Acupressure
Procedure
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2010 · Synced May 21, 2026, 4:39 PM EDT
Enrolling by invitation No phase listed Observational
View directory record Official record
Conditions
Gastroparesis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dexamethasone, dronabinol, palonosetron hydrochloride, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Springfield, Missouri • Greenville, South Carolina • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ginger, Placebo Oral Tablet
Drug
Lead sponsor
Joel Yarmush
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced May 21, 2026, 4:39 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Nausea and Vomiting Chemotherapy-Induced
Interventions
Medical Cannabis
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced May 21, 2026, 4:39 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cholecystitis, Acute, Cholelithiasis, Nausea, Postoperative, Vomiting, Postoperative, Pain, Postoperative
Interventions
Acupuncture
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 4:39 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Dexamethasone, Aprepitant
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced May 21, 2026, 4:39 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Glycopyrrolate, Normal Saline
Drug
Lead sponsor
Kokila N Thenuwara
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
dexamethasone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 7 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced May 21, 2026, 4:39 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Bariatric Surgery Candidate, Postoperative Nausea and Vomiting, Morbid Obesity
Interventions
Bariatric Full Liquid Diet
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
APD421, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Miami, Florida • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Bakersfield, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced May 21, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Pregnancy Emesis
Interventions
Aromatherapy, Placebo
Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
ondansetron, survey administration, management of therapy complications
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
PONV
Interventions
APD421- Amisulpride for IV injection, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced May 21, 2026, 4:39 PM EDT